Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CORCEPT THERAPEUTICS INCCORT · Entity 2620 | Director | September 10, 2025 | September 12, 2025 |
| Xenon Pharmaceuticals Inc.XENE · Entity 2602 | Director | June 05, 2026 | June 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CORCEPT THERAPEUTICS INC
Report date September 10, 2025 · Filed September 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-09-10 transaction · row 1
1 source rowRow 1 · 2025-09-10 · Gift · Disposed 7,393 · Balance 0 F1: Represents a donation by the Reporting Person to Fidelity Charitable Giving Account. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a donation by the Reporting Person to Fidelity Charitable Giving Account.
Xenon Pharmaceuticals Inc.
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 1,455 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Sale · Disposed 1,190 · Balance 1,455 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted by the reporting person on August 15, 2025, solely to satisfy income tax obligations related to the vesting of RSUs granted on June 5, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted by the reporting person on August 15, 2025, solely to satisfy income tax obligations related to the vesting of RSUs granted on June 5, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 9, 2026 01:19 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 1,190 | $53.14 | $63,236.60 |
DisclosureSEC source: 0001193125-26-262671 · ownership.xml · nonDerivative · entry 1 Cannon Gillian · CIK 0001833910 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,455 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted by the reporting person on August 15, 2025, solely to satisfy income tax obligations related to the vesting of RSUs granted on June 5, 2025. Read SEC document |
| June 03, 2026 Filed Jun 4, 2026 01:03 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantRestricted Share Units · Derivative | 1,593 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-256120 · ownership.xml · derivative · entry 4 Cannon Gillian · CIK 0001833910 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,593 Underlying: Common Shares · 1,593 shares Expires not disclosed F3 · derivative.exercise_date: Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders. F3 · derivative.expiration_date: Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders. Read SEC document |
| June 03, 2026 Filed Jun 4, 2026 01:03 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantShare Option (Right to Buy) · Derivative | 10,507 | $0.00 Strike: $53.46 | $0.00 |
DisclosureSEC source: 0001193125-26-256120 · ownership.xml · derivative · entry 3 Cannon Gillian · CIK 0001833910 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,507 Underlying: Common Shares · 10,507 shares Expires 2036-06-02 F2 · derivative.exercise_date: Vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders. Read SEC document |
| June 01, 2026 Filed Jun 4, 2026 01:03 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionRestricted Share Units · Derivative | 2,645 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-256120 · ownership.xml · derivative · entry 2 Cannon Gillian · CIK 0001833910 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 2,645 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders. F1 · derivative.exercise_date: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders. F1 · derivative.expiration_date: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders. Read SEC document |
| June 01, 2026 Filed Jun 4, 2026 01:03 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 2,645 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-256120 · ownership.xml · nonDerivative · entry 1 Cannon Gillian · CIK 0001833910 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,645 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders. F1 · price: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 01:03 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 7,393 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-201561 · ownership.xml · nonDerivative · entry 1 Cannon Gillian · CIK 0001833910 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Represents a donation by the Reporting Person to Fidelity Charitable Giving Account. Read SEC document |
| September 04, 2025 Filed Sep 9, 2025 00:20 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 11,000 | $0.00 Strike: $22.99 | $0.00 |
DisclosureSEC source: 0001193125-25-198568 · ownership.xml · derivative · entry 3 Cannon Gillian · CIK 0001833910 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,000 Underlying: Common Stock · 11,000 shares Expires 2030-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| September 04, 2025 Filed Sep 9, 2025 00:20 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 3,607 | $70.13 | $252,958.91 |
DisclosureSEC source: 0001193125-25-198568 · ownership.xml · nonDerivative · entry 2 Cannon Gillian · CIK 0001833910 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,393 F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price from a net (cashless) exercise of options. Read SEC document |
| September 04, 2025 Filed Sep 9, 2025 00:20 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 11,000 | $22.99 | $252,890.00 |
DisclosureSEC source: 0001193125-25-198568 · ownership.xml · nonDerivative · entry 1 Cannon Gillian · CIK 0001833910 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 00:53 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $72.27 | $0.00 |
DisclosureSEC source: 0000950170-25-085772 · ownership.xml · derivative · entry 1 Cannon Gillian · CIK 0001833910 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2035-06-10 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of June 10, 2025 over a one-year period, subject to Reporting Person's continued service on each monthly vesting date. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 21:57 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantRestricted Share Units · Derivative | 2,645 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-083318 · ownership.xml · derivative · entry 2 Cannon Gillian · CIK 0001833910 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,645 Underlying: Common Shares · 2,645 shares Expires not disclosed F2 · derivative.exercise_date: Each restricted share unit represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders. F2 · derivative.expiration_date: Each restricted share unit represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 21:57 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantShare Option (Right to Buy) · Derivative | 17,012 | $0.00 Strike: $30.73 | $0.00 |
DisclosureSEC source: 0000950170-25-083318 · ownership.xml · derivative · entry 1 Cannon Gillian · CIK 0001833910 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,012 Underlying: Common Shares · 17,012 shares Expires 2035-06-04 F1 · derivative.exercise_date: Vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders. Read SEC document |
| June 05, 2024 Filed Jun 5, 2024 21:41 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 15,542 | $0.00 Strike: $38.16 | $0.00 |
DisclosureSEC source: 0000950170-24-069463 · ownership.xml · derivative · entry 1 Cannon Gillian · CIK 0001833910 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,542 Underlying: Common Shares · 15,542 shares Expires 2034-06-04 F1 · derivative.exercise_date: Vesting 100% on the earlier of (i) June 4, 2025 or (ii) the day before the date of the issuer's 2025 annual meeting of shareholders. Read SEC document |
| May 17, 2024 Filed May 21, 2024 22:25 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock option (right to buy) · Derivative | 30,000 | $0.00 Strike: $28.09 | $0.00 |
DisclosureSEC source: 0000950170-24-063156 · ownership.xml · derivative · entry 1 Cannon Gillian · CIK 0001833910 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-05-16 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 17, 2024 over a one-year period. Read SEC document |
| August 10, 2023 Filed Aug 10, 2023 22:56 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $38.39 | $0.00 |
DisclosureSEC source: 0000950170-23-041528 · ownership.xml · derivative · entry 1 Cannon Gillian · CIK 0001833910 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Shares · 28,000 shares Expires 2033-08-09 F1 · derivative.exercise_date: One-third of the total shares subject to the Option shall vest on the first anniversary of August 8, 2023 (the "Start Date"), one-third on the second anniversary of the Start Date and the balance on the third anniversary of the Start Date. Read SEC document |
| May 19, 2023 Filed May 23, 2023 21:00 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock option (right to buy) · Derivative | 30,000 | $0.00 Strike: $24.10 | $0.00 |
DisclosureSEC source: 0000899243-23-013737 · doc4.xml · derivative · entry 1 Cannon Gillian · CIK 0001833910 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-05-18 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 19, 2023 over a one-year period. Read SEC document |
| May 31, 2022 Filed Jun 2, 2022 21:00 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $20.84 | $0.00 |
DisclosureSEC source: 0000899243-22-020702 · doc4.xml · derivative · entry 1 Cannon Gillian · CIK 0001833910 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-05-30 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 31, 2022 over a one-year period. Read SEC document |
| May 26, 2021 Filed May 28, 2021 21:05 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $21.45 | $0.00 |
DisclosureSEC source: 0000899243-21-021130 · doc4.xml · derivative · entry 1 Cannon Gillian · CIK 0001833910 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-05-25 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 26, 2021 over a one-year period. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 00:26 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $22.99 | $0.00 |
DisclosureSEC source: 0000899243-20-032579 · doc4.xml · derivative · entry 1 Cannon Gillian · CIK 0001833910 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-12-01 F1 · derivative.exercise_date: Shares subject to the stock option vest and become exercisable with respect to 25% of the shares on the first anniversary of the date of grant and, thereafter, at the rate of 2.08334% of the total number of shares per month, until fully vested and exercisable on the fourth anniversary of the date of grant, subject to the Reporting Person's continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.